Novadaq Corp. Announces First Quarter 2007 Conference Call and Webcast and Annual Meeting

TORONTO, May 1 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. , a developer of real-time medical imaging systems and image guided therapies for the operating room, will host a conference call and live webcast to discuss the financial results for the first quarter ended March 31, 2007. The Company will also host its annual meeting on Tuesday, May 15 to discuss fiscal 2006. Both meetings will be hosted by Dr. Arun Menawat, President and Chief Executive Officer, and Mr. Roger Deck, Chief Financial Officer.

QUARTERLY CONFERENCE CALL Date: May 7, 2007 Time: 4:30 pm, Eastern Time Dial in number: 416-644-3425 or 1-800-591-7539 Taped replay: 416-640-1917 or 1-877-289-8525 (Available until May 14th, 2007) Code number: 21231178 Webcast: A live audio webcast of the call will be available at www.novadaq.com. Webcast attendees are welcome to listen to the conference in real-time or on-demand at your convenience. The webcast will be archived for 90 days. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. ANNUAL MEETING Date: May 15, 2007 Time: 10:30 am, Eastern Time Location: The National Club, Howland Room 303 Bay St. Toronto, Ontario, Canada Webcast: A live audio webcast of the call will be available at www.novadaq.com. Webcast attendees are welcome to listen to the conference in real-time or on-demand at your convenience. The webcast will be archived for 90 days. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. About Novadaq Technologies

Novadaq Technologies Inc. develops and commercializes medical imaging systems and real-time image guided therapies for use in the operating room. Novadaq's proprietary imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. Novadaq's SPY(R) Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart surgery. Novadaq's OPTTX(R) System which received CE Mark approval in November 2006, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The HELIOS(TM) Imaging System, which received FDA clearance in January 2007, is the first fluorescent imaging system available for use during plastic reconstructive surgery allowing surgeons to evaluate pre- and intra-operative blood flow, as well as post-surgery perfusion. Novadaq's LUNA(TM) Imaging System is designed to enable surgeons to visualize nerve bundles during the course of urological and neurological procedures. LUNA(TM) has been granted a license for use by Health Canada. Novadaq is also the exclusive United States distributor of PLC Medical's CO(2) HEART LASER(TM) System for TMR (Trans-Myocardial Revascularization). For more information, please visit the company's website at www.novadaq.com.

Forward-looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments, including (among other matters) that Novadaq will complete its proposed private placement on the basis described herein or at all. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: visit our website at www.novadaq.com, or contact: Arun Menawat,PhD, MBA President & CEO Novadaq Technologies Inc., (905) 629-3822 x 202,amenawat@novadaq.com; Michael Moore, Investor Relations, The Equicom Group,(416) 815-0700 x 241, mmoore@equicomgroup.com